Fig. 1 · Structure

Documents & Downloads

Norverapamil hydrochloride

Cat. No. A12249 CAS 67812-42-4

P-gp inhibitor

Norverapamil hydrochloride ((±)-Norverapamil hydrochloride), an N-demethylated metabolite of Verapamil, is a L-type calcium channel blocker and a P-glycoprotein (P-gp) function inhibitor.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Norverapamil hydrochloride Research Summary

This section summarizes 2 in vitro studies of Norverapamil hydrochloride from 1 published reference. In vitro models include Mtb mc26206.

Norverapamil hydrochloride In Vitro Studies

Norverapamil was evaluated in Mtb mc26206 using intracellular EtBr accumulation and FITC-rifampicin efflux readouts. Norverapamil inhibited both efflux activities, although less than the other compounds. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Intracellular EtBr accumulation in Mtb

Cell-based study · Mtb mc26206 [1]

Mtb mc26206 was treated with Norverapamil at 25 μM to assess intracellular EtBr accumulation against a control without drug. Norverapamil inhibited both efflux activities, although less than the other compounds.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Percent increase in intracellular EtBr accumulationReported result Norverapamil also inhibited both efflux activities albeit less than the other compounds[1]

Literature-Reported Treatment Conditions

Treatment concentration
25 μM
Exposure duration
until steady state was reached, typically after 90 min
Reported limits
Not stated in the sentences used: route, vehicle.
Methods and source locations

Compound reported in the paper: Norverapamil

The paper names Norverapamil without stating the salt or form; not verified as the hydrochloride form supplied as A12249. No dose conversion or lot validation.

Results > Verapamil’s Inhibition of Mtb Efflux Pumps Is Linked to Its Human P-glycoprotein (PGP) Inhibitory Activity. (S47); Materials and Methods > EtBr Accumulation Assay. (S108, S110); Fig. 3. legend (S164)

Percent increase in intracellular EtBr accumulation: Percent increase in intracellular EtBr accumulation; comparator: without drug present — Results > Verapamil’s Inhibition of Mtb Efflux Pumps Is Linked to Its Human P-glycoprotein (PGP) Inhibitory Activity. (S47); Fig. 3. legend (S164)

FITC-rifampicin efflux in Mtb

Cell-based study · Mtb mc26206 [1]

Mtb mc26206 was treated with Norverapamil at 25 μM to assess FITC-rifampicin efflux against an untreated group. Norverapamil inhibited both efflux activities, although less than the other compounds.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Percent inhibition of FITC-rifampicin effluxReported result Norverapamil also inhibited both efflux activities albeit less than the other compounds[1]

Literature-Reported Treatment Conditions

Treatment concentration
25 μM
Exposure duration
24-h final sampling time
Reported limits
Not stated in the sentences used: route, vehicle.
Methods and source locations

Compound reported in the paper: Norverapamil

The paper names Norverapamil without stating the salt or form; not verified as the hydrochloride form supplied as A12249. No dose conversion or lot validation.

Results > Verapamil’s Inhibition of Mtb Efflux Pumps Is Linked to Its Human P-glycoprotein (PGP) Inhibitory Activity. (S47); Materials and Methods > Quantification of FITC-Rifampicin Efflux. (S114, S122, S123); Fig. 3. legend (S165)

Percent inhibition of FITC-rifampicin efflux: Percent inhibition of FITC-rifampicin efflux; comparator: untreated group — Results > Verapamil’s Inhibition of Mtb Efflux Pumps Is Linked to Its Human P-glycoprotein (PGP) Inhibitory Activity. (S47); Fig. 3. legend (S165)

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor, Blocker
CAS Number 67812-42-4
Applications P-gp inhibitor
Formula C26H37ClN2O4
Molecular Weight 477.04
Synonyms (±)-Norverapamil hydrochloride; D591 hydrochloride
SMILES
N#CC(C(C)C)(CCCNCCC1=CC=C(OC)C(OC)=C1)C2=CC=C(OC)C(OC)=C2.[H]Cl

Storage & Solubility

In Vitro Solubility

Reported Solubility

No reported solubility data are available for this product.

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Norverapamil hydrochloride Research References

  1. [1] Lake MA, Adams KN, Nie F, et al. The human proton pump inhibitors inhibit Mycobacterium tuberculosis rifampicin efflux and macrophage-induced rifampicin tolerance. Proc Natl Acad Sci U S A (2023). PMID: 36763530 DOI: 10.1073/pnas.2215512120 Source material

Added to your cart

View Cart Checkout
Loading...